Business Context and Reporting Period
This Form 8-K filing by RXi Pharmaceuticals Corporation (also referred to as Phio Pharmaceuticals Corp. in metadata) covers the reporting period of May 2, 2016. The report addresses a specific corporate event regarding the company's listing status on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance and corporate actions rather than financial performance data.
Material Changes
The primary material change reported is the company regaining compliance with the Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement. This compliance was achieved following the implementation of a one-for-ten reverse split of the company's common stock, which became effective on April 18, 2016.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies beyond the immediate context of the reverse split and listing compliance. The unusual item noted is the receipt of the Notification Letter from the Nasdaq Stock Market, LLC confirming the regained compliance status.
Investor Verification Checklist
- Verify the effective date of the one-for-ten reverse split (April 18, 2016).
- Confirm the current minimum bid price of the stock to ensure continued compliance with Nasdaq rules.
- Review the prior Form 8-K filed on April 15, 2016, for detailed information regarding the reverse split mechanics.
- Check subsequent filings for any updates on the company's financial status or operational progress.